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Abstract 
BACKGROUND: Renal biopsy performed in native and transplant kidneys is generally considered a safe 
procedure.  
AIM: In this study, we evaluated renal biopsy complications and risk factors in one nephrology facility.  
MATERIAL AND METHODS: We conducted a three-year retrospective study on patients who underwent renal 
biopsy between January 2014 and December 2016. Strict written biopsy protocol was followed. Clinical and 
laboratory data were obtained from medical charts. Complications were categorised as minor and major, 
according to the need for intervention. Minor complications included macrohematuria and/or hematoma that did 
not require intervention. Major complications included hematuria or hematoma with fall of hematocrit that required 
a blood transfusion, surgery or caused death. A binary logistic regression model was used to analyse the possible 
factors associated with complications after the biopsy.  
RESULTS: We analysed 345 biopsies; samples were taken from patients aged from 15-81 years, of whom 61% 
were men. A total of 21 (6%) patients developed a complication, 4.4% minor and 1.7% major complications. There 
were no nephrectomy or death due to biopsy intervention. Overweight patients, as well as those with higher 
creatinine, lower hemoglobin, higher blood pressure and biopsy due to AKI had higher chances to develop 
complications (p = 0.037, p = 0.023, p = 0.032, p = 0.002, p = 0.002, respectively). The patients’ age, gender, 
kidney dimension, number of passes and uninterrupted aspirin therapy were not found as significant predictors of 
complications. In the multivariate logistic model, body weight (OR = 1.031, 95%CI = 1.002-1.062), lower 
hemoglobin (OR = 0.973, 95%CI = 0.951–0.996) and hypertension (OR = 1.025, 95%CI = 1.007-1.044) increased 
the risk of complications in biopsied patients. 
CONCLUSION: Renal biopsy is a safe procedure with a low risk of complications when strict biopsy protocol is 
observed. Correction of anaemia and blood pressure is to be considered before the biopsy. 
 
 
 
 
 
Introduction 
 
In spite of the continuous research on new 
biomarkers and other renal function non-invasive 
diagnostic tools, percutaneous renal biopsy remains a 
gold standard procedure for the diagnosis of renal 
disease [1]. It is performed in native and transplanted 
kidneys and is generally considered a safe procedure 
[2], [3]. The use of ultrasound guidance and 
automated biopsy gun provide a low risk of 
complications such as pain, bleeding, or a small 
hematoma. Major complications, including the need 
for nephrectomy or death, are extremely rare [4]. 
However, controversies persist regarding the optimal 
assessment and management of the bleeding risk [5], 
different pre and after procedure protocols, especially 
for the solitary native kidney, the optimal duration of 
observation and the possibility of performing it on an 
outpatient basis. Potential risk factors for bleeding 
complications are the female sex, elevated blood 
pressure, disturbed hemostasis and low haemoglobin 
level before intervention [6]. The risk of bleeding 
appears to be lower for transplant than for native 
kidney biopsy [7]. An outpatient programmed biopsy is 
considered to be with lower risk because of the better 
clinical status of the patient. It is also lower for the 
protocol transplant biopsies. On the other hand, for 
biopsies in patients with higher creatinine and acute 
kidney insufficiency, the risk of bleeding is expected to 
be higher [5].  
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In this study, we evaluated the kidney biopsy 
complications and the risk for bleeding in our 
nephrology facility. 
 
 
Material and Methods 
 
Study design 
A retrospective observational study was 
performed with biopsied patients, hospitalised in the 
nephrology academic tertiary clinic. 
 
Study population 
We analysed the medical charts of all the 
patients who underwent renal biopsy (native or 
transplant), between January 2014 and December 
2016. All subjects were 15-81 years of age, free of 
infection. All of the study procedures were conducted 
by the written protocols, and informed consent was 
provided. 
 
Data collection 
We collected data for the clinical parameters 
including gender, age (years), body weight (kg), 
history of hypertension, acute or chronic renal disease 
and proteinuria. Hypertension was defined as an 
average home systolic blood pressure higher than 140 
mmHg before medication. Serum data were collected: 
creatinine (µmol/L), haemoglobin (g/L), platelet count 
(x10
9
/L), prothrombin time (seconds) and activated 
thromboplastin time (seconds). Post-biopsy urinary 
tract infection was defined as symptoms of frequency, 
urgency, or pyuria. Hematoma or hydronephrosis was 
detected by ultrasound. The number of biopsy 
attempts and the number of obtained tissue cores was 
noted for each biopsy.  
 
Biopsy protocol 
Before biopsy, patients were controlled for 
systolic blood pressure (not to exceed 180 mmHg). 
Antiplatelet or antithrombotic agents (e.g. aspirin, 
GPII/IIIa inhibitors, dipyridamole and nonsteroidal 
inflammatory drugs) were discontinued at least 5 days 
before biopsy and the prothrombin time had to be 
normalised. Pentoxifylline was not to be taken within 1 
day before the biopsy. One day before the biopsy, 
platelet count, prothrombin time and activated partial 
thromboplastin time had to be normal. A biopsy was 
not performed in patients with platelets under 100 and 
abnormal coagulation. The biopsy procedure, its risks 
and benefits were explained to the patient. The 
biopsies from the native kidneys were performed 
under real-time ultrasound guidance in a prone 
position with a pillow under the abdomen in order to 
reduce lumbar lordosis. Transplanted patients were 
placed in supine position. The patients cooperated by 
holding their breath for a few seconds. A spinal needle 
was used to locate the capsule of the lower pole and 
to provide local anesthesia for the biopsy. Two cores 
of renal tissue measuring one cm in length were 
obtained. An automated spring-loaded biopsy device 
and size of the needle 16 G were used. Immediately 
after biopsy, check for any bleeding hematoma by 
ultrasound was performed. Patients were instructed to 
maintain a supine posture in bed for several hours 
and bed rest overnight was recommended for 
programmed biopsy admissions. Vital signs were 
closely monitored after the biopsy. If any gross 
hematuria, back or abdominal pain, dizziness or 
nausea were noted, urinalysis, haemoglobin and 
serum examinations were conducted. Additional 
imagining investigations including additional 
sonography were performed when clinically indicated 
at the discretion of the attending physician. 
Complications (hematoma, hematuria, 
hydronephrosis, blood transfusions, haemoglobin 
decline, angiographic intervention, nephrectomy and 
other treatments or death) were all recorded. 
Complications were categorised as minor and major. 
Minor complications included macrohematuria and/or 
hematoma that did not require intervention such as 
blood transfusion or angiography. Major complications 
included hematuria or hematoma with fall of 
hematocrit that required a blood transfusion, 
angiography, surgery or caused hypotension that 
required intervention. 
 
Statistical methods 
Data were expressed as the mean ± standard 
deviation for continuous variables and as 
frequency/percentage for categorical variables. 
Demographic and clinical characteristics of the entire 
cohort were recorded. A binary logistic regression 
model was used to analyse the possible factors 
associated with complications after the biopsy. A P 
value of less than 0.05 was considered significant. All 
statistical methods were performed using the SPSS 
statistical software package, version 17.0  
 
 
Results 
 
We analysed 345 biopsies performed in 342 
patients with the native or transplanted kidney in three 
consecutive years, with a mean of 115 biopsies per 
year. Baseline demographics are shown in Table 1. 
Female patients and those with transplanted kidney 
were less frequently biopsied (39% and 14%, 
respectively). In a large percentage of patient’s 
elective biopsy was performed (69%) and in 43 
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patients the indication was due to acute kidney injury 
(AKI). The mean systolic blood pressure was under 
140 mmHg (136.02 ± 21.72 mmHg), but the history of 
hypertension was present in a vast majority of the 
patients (74%). The size of the biopsied kidney varied 
between 87-155 mm and mean pre-biopsy creatinine 
level was 263.79 µmol/L. Patients body weight varied 
between 30-125 kg, 29% were ≥ 80 kg. In 1.4% of the 
patients, therapy with aspirin was not interrupted due 
to biopsy. Technical success (a produced specimen) 
was achieved in 339 (99.12%) patients. Specimen 
inadequacy occurred in 3 (0.88%), and those biopsies 
were subsequently repeated. Mean pre-biopsy 
haemoglobin level was 116 g/L and it dropped after 
biopsy by less than 10 g/L in 12.6% of patients and by 
more than 10 g/L in nearly 7% of patients. 
Table 1: Demographic and clinical data of the patients 
Baseline data N (%) mean ± SD 
Male (%) 211 (61) 
Mean age (years) 47.75 ± 15.5 
Body weight (Kg) >80 kg 99 (29%) 
Pre-biopsy-Hb (g/L) 116.96 ± 22.49 
Hb change (g/L) 1.38 ± 6.78
a
 
Hb change >10 g/L (%) 24 (6.9) 
a
 
Platelets (x10
9
/L) 242.03 ± 75.29 
Systolic BP (mmHg) 136.02 ± 21.72 
Creatinine (µmol/L) 263.79 ± 272.11 
History of Hypertension (%) 256 (74) 
Solitary native kidney (%) 3 (0.86) 
Transplanted kidney (%) 49 (14.2) 
Indication due to AKI (%) 43 (12.5) 
Elective biopsy (%) 241 (69.9) 
Indication due to proteinuria (%) 222 (64.3) 
Small sized kidney (<100 mm length) (%) 48 (13.9) 
Aspirin (%) 5 (1.4) 
Passes  2.09 ± 0.34 
Cores  2.02 ± 0.3 
Second biopsy (%) 3 (0.88) 
Hb – haemoglobin, BP - blood pressure, 
a
vailable in 296. 
 
A total of 21 (6%) patients developed a 
complication (Table 2). There were 15 (4.4%) minor 
and 6 (1.7%) major complications. The patients who 
developed major complications received blood 
transfusion therapy. The most common complication 
was hematuria (4.9%). Large and small hematoma 
occurred in 4 patients, but only in two blood 
transfusion was required. One patient was transferred 
to ICU because of severe hypotension and one to 
surgery, but there were no nephrectomy or death due 
to the biopsy intervention. No urinary infection or 
hydronephrosis occurred. 
Table 2: Complications following a kidney biopsy 
Complication n (%) 
Hematuria 17 (4.9) 
Hematoma (> 5 cm) 2 (0.6) 
Hypotension/shock 2 (0.6) 
Minor complications 15 (4.4) 
Major complications 6 (1.7) 
 
Identification of significant independent 
predictors of complications was performed by entering 
factors in the univariate model of logistic regression. 
Overweight patients, those with higher creatinine, 
lower hemoglobin, higher blood pressure and biopsy 
due to AKI had higher chances to develop 
complications (p = 0.037, p = 0.023, p = 0.032, p = 
0.002, p = 0.002, respectively). The patients’ age, 
gender, kidney dimension, number of passes and 
uninterrupted aspirin therapy were not found as 
significant predictors of complications. In transplanted, 
solitary native kidney and programmed biopsies, the 
risk was also insignificant. In the multivariate logistic 
model, the higher body weight (p = 0.037), lower 
hemoglobin (p = 0.02) and hypertension (p = 0.007) 
aggravated the risk of complications in biopsied 
patients (Table 3).  
Table 3: Binary logistic regression of factors associated with 
increased risk for major bleeding 
Risk factor Odds Ratio 95% confidential interval P-value 
Body weight 1.031 1.002 to 1.062 0.037 
Hemoglobin 0.973 0.951 to 0.996 0.02 
Hypertension 1.025 1.007 to 1.044 0.007 
 
 
 
Discussion 
 
Chronic kidney disease is a worldwide 
problem and determination of the diagnosis by biopsy 
is of great value in the early treatment of those 
patients. Renal biopsy is usually recognised as a safe 
procedure in native and transplanted kidneys [6], [8], 
[9], [10]. Brachemi’s review on large clinical trials 
provided an estimate of the frequency of 
complications after renal biopsy with required blood 
transfusions from 0.3% to 10% and death due to 
biopsy in less than 0.1% (5). In our analysis, 
complications that required blood transfusions were 
classified as major complications, and their number 
was rather low – 6 (1.7%). Also, we had no deaths or 
nephrectomies. Hematuria was noted as the most 
frequent complication in many studies, ranging from 
1.9% up to 10% [6], [11], [13]. In our study, not only 
gross hematuria but also the lightest transient ones 
were recorded. It occurred in 17 (4.9%) patients. 
Thirteen of those patients did not need any blood 
transfusion. Symptomatic hematoma occurred in only 
two cases (0.6%), which was less than that presented 
in other studies [14], [15].  
In the assessment of the factors associated 
with biopsy complications, our results confirmed the 
previously recognised traditional bleeding factors. 
Higher serum creatinine and AKI were significant 
confounding factors in biopsy complications in a large 
multicentric study on 2563 patients [16] but were also 
found in smaller monocentric studies, as ours [8], [11]. 
In our results, these factors lost statistical significance 
in the multivariate model. Arterial hypertension was 
found to double the bleeding risk in an analysis of 462 
biopsies [14]. Similar results were published by the 
Norwegian registry on 8573 biopsies [6]. Still, there 
were studies which did not confirm this association [8], 
[9] emphasising the history of hypertension as a factor 
and not the present blood pressure. In our study 
group, the vast majority of patients had a history of 
hypertension (74%), but only current hypertension 
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increased the bleeding risk as an independent 
predictor. As previously published, the lower pre-
biopsy hemoglobin level [4], [11] was also associated 
with higher risk of complications in our patients. 
Hemoglobin dropped after biopsy for more than 10 g/L 
in 6.9% of the patients, but blood transfusion was 
needed in only 1.7%. This fact also partly explained 
the data that the lower the hemoglobin the higher the 
risk of need for transfusion. The indication for a kidney 
biopsy from a solitary kidney remains an important 
decision with regards to safety issues and a potential 
nephrectomy [5]. Only three solitary native kidneys 
were biopsied in the analyzed period of three years. 
None of those patients showed any complication. In 
the group of transplanted patients (14.2%), only one 
patient had severe bleeding, but recovered well. This 
low grade of complications in graft biopsies has been 
confirmed in many studies comparing native and 
transplanted kidneys [15], [17], [18]. 
Considering the coagulability as a major 
concern for bleeding complications, before biopsy in 
all our patients, platelet count was within reference 
values (Table 1). Antiplatelet or antithrombotic agents 
were to be withheld 5 days before biopsy. In 5 (1.4%) 
of our cases, aspirin was not interrupted at the 
discretion of the physician, and no bleeding 
complications occurred. Recent studies support the 
strategy of not stopping aspirin before renal biopsy in 
native [16] and transplanted kidneys [19], 
demonstrating a similar safety profile of the 
procedure. Obesity is a growing problem in modern 
medicine. Conventional biopsy is difficult to perform in 
obese patients and hence, an alternative approach 
has been developed [20]. In Lees study on 2563 
native renal biopsies, there was no increased risk in 
obese (BMI > 30) patients [16]. But in our study, the 
body weight was found associated with a higher risk 
of bleeding complication.  
In all 342 patients, 345 biopsies were 
performed with a standard 16 Ga needle, with two or 
three passes. The number of passes did not affect the 
risk of complications, which is in line with previous 
studies [14]. 
In conclusion, renal biopsy is a safe 
procedure with a low risk of complications. Careful 
assessment of the risk for complications should be 
performed before the biopsy. Strict biopsy protocol 
must be observed. Correction of anaemia and blood 
pressure is to be considered before the biopsy.  
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